Heron Therapeutics Management
Management criteria checks 1/4
Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 1.08 years. directly owns 0.16% of the company’s shares, worth $712.71K. The average tenure of the management team and the board of directors is 1 years and 2.7 years respectively.
Key information
Craig Collard
Chief executive officer
US$5.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates
Aug 11Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now
Jun 11Heron Therapeutics files for 12.4M common stock offering from shareholder
May 28Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
May 19Heron Therapeutics EPS misses by $0.03, misses on revenue
May 10Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit
Mar 10Does Heron Therapeutics (NASDAQ:HRTX) Have A Healthy Balance Sheet?
Feb 03
CEO
Craig Collard (57 yo)
1.1yrs
Tenure
US$5,486
Compensation
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$5.49k | 0.16% $ 712.7k | |
| Executive VP & CFO | less than a year | US$1.76m | 0.058% $ 264.1k | |
| Executive VP & Chief Development Officer | less than a year | US$1.71m | 0.055% $ 249.5k | |
| Vice President of Marketing | less than a year | no data | no data | |
| Senior Vice President of Human Resources | 8.7yrs | no data | no data | |
| Senior VP of Oncology Care Franchise & Commercial Operations | 1.3yrs | no data | no data | |
| Executive Director | no data | no data | no data |
1.0yrs
Average Tenure
54yo
Average Age
Experienced Management: HRTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.49k | 0.16% $ 712.7k | |
| Independent Director | 10.3yrs | US$11.02m | 0.034% $ 156.2k | |
| Independent Director | 7.9yrs | US$70.51k | 0.035% $ 157.2k | |
| Independent Director | 2.7yrs | US$65.63k | 0.035% $ 159.3k | |
| Independent Chairman | 1.3yrs | US$545.53k | 0.0063% $ 28.5k | |
| Independent Director | 2.7yrs | US$55.00k | 0.035% $ 159.3k |
2.7yrs
Average Tenure
56.5yo
Average Age
Experienced Board: HRTX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.